Enlivex secures $21 million debt financing

Longevity pharmaceutical company Enlivex has successfully closed a $21 million debt financing agreement with The Lind Partners, a New York-based institutional fund manager. This funding is expected to support the company's ongoing operations and strategic initiatives within the pharmaceutical sector. The deal highlights continued investor confidence in Enlivex's business model and its potential for growth in the specialized field of longevity research and development.